

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

27 May 2026

### The effect of zinc supplementation on inflammatory responses and total blood cells counts of patients who infected with COVID-19

#### Protocol summary

##### Study aim

Determining the effect of zinc supplementation on inflammatory activity and blood cell status in patients with COVID-19

##### Design

This study is a double-blind randomized controlled clinical trial with parallel groups. The randomization of individuals to the intervention or control group will be done with SPSS software.

##### Settings and conduct

The study will be performed at Shohada Tajrish Hospital in Tehran. The evaluation of variables will be done at the beginning and end of the study by sampling the patient's blood. The intervention group will receive zinc gluconate supplementation for two weeks and the control group will receive the same number of placebo.

##### Participants/Inclusion and exclusion criteria

We will invite 44 patients with COVID-19 to enter the study based on inclusion and exclusion criteria. Inclusion criteria: 1. Being 20 to 60 years old 2. Detection of COVID-19 based on PCR test 3. Willingness to participate in the study 4. Do not take antibiotics and vitamin D 5. Not breastfeeding or pregnant 6. No advanced respiratory distress syndrome leading to intubation 7. No history of alcohol and tobacco use Exclusion criteria: 1. Taking antioxidant supplements while studying 2. Alcohol and tobacco consumption during the study

##### Intervention groups

Intervention group: Includes 22 patients with COVID-19 who, in addition to their usual treatments, will take 3\*30 mg zinc capsules daily for 2 weeks after meals. Control group: Includes 22 patients with COVID-19 who, in addition to their usual treatments, will take 3 placebo capsules (maltodextrin) daily for 2 weeks after meals. Placebo capsules are exactly the same in appearance, color, smell and shape as zinc capsules.

##### Main outcome variables

1. Serum C-Reactive Protein level 2. Serum Interleukin-6 level 3. leukocyte count 4. Total Lymphocyte Count 5.

Absolute neutrophil count

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210204050238N1**

Registration date: **2021-03-02, 1399/12/12**

Registration timing: **prospective**

Last update: **2021-03-02, 1399/12/12**

Update count: **0**

##### Registration date

2021-03-02, 1399/12/12

##### Registrant information

##### Name

Morteza Khamoushi

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 21 8895 5975

##### Email address

mortezakhamoushi@gmail.com

##### Recruitment status

**Recruitment complete**

##### Funding source

##### Expected recruitment start date

2021-03-21, 1400/01/01

##### Expected recruitment end date

2021-07-22, 1400/04/31

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

### Scientific title

The effect of zinc supplementation on inflammatory responses and total blood cells counts of patients who infected with COVID-19

### Public title

The effect of zinc supplementation on COVID-19

### Purpose

Supportive

### Inclusion/Exclusion criteria

#### Inclusion criteria:

Being 20 to 60 years old  
Detection of COVID-19 based on PCR test and ward admission  
Willingness to participate in the study  
Intravenous daily intake of 8 mg dexamethasone

#### Exclusion criteria:

Taking antibiotics and vitamin D.  
Advanced Respiratory Distress Syndrome leading to intubation or hospitalization in the intensive care unit  
History of alcohol and tobacco use

### Age

From **20 years** old to **60 years** old

### Gender

Both

### Phase

N/A

### Groups that have been masked

- Participant
- Care provider
- Investigator
- Outcome assessor
- Data analyser

### Sample size

Target sample size: **44**

### Randomization (investigator's opinion)

Randomized

### Randomization description

Each person is assigned a code and this code is entered into Excel software, randomization will be done using rand function of Excel software.

### Blinding (investigator's opinion)

Double blinded

### Blinding description

Physicians and ward nurses are blind about the study group. Patient is blind about the study group. investigator is blind about the study group. data analyzer is blind about the study group. Assignment of patients in treatment and placebo groups is performed by a nurse out of above mentioned groups.

### Placebo

Used

### Assignment

Parallel

### Other design features

## Secondary Ids

empty

## Ethics committees

### 1

#### Ethics committee

##### Name of ethics committee

Vice-Chancellor in Research Affairs- Tehran University of Medical Sciences

##### Street address

central headquarters of Tehran University of Medical Sciences, Keshavarz Boulevard, Tehran, Iran

##### City

Tehran

##### Province

Tehran

##### Postal code

3439123900

#### Approval date

2020-12-05, 1399/09/15

#### Ethics committee reference number

IR.TUMS.MEDICINE.REC.1399.849

## Health conditions studied

### 1

#### Description of health condition studied

COVID-19

#### ICD-10 code

U07.1 COVI

#### ICD-10 code description

COVID-19 , virus identified

## Primary outcomes

### 1

#### Description

Serum C-Reactive Protein level

#### Timepoint

The first day and the last day of the intervention

#### Method of measurement

blood analysis

### 2

#### Description

Serum Interleukin-6 level

#### Timepoint

The first day and the last day of the intervention

#### Method of measurement

Using blood, serum IL-6 value in Picograms per deciliter by Kit

### 3

#### Description

blood leukocyte count

#### Timepoint

The first day and the last day of the intervention

#### Method of measurement

blood analysis

#### 4

**Description**

Total Lymphocyte Count

**Timepoint**

The first day and the last day of the intervention

**Method of measurement**

blood analysis

#### 5

**Description**

Absolute neutrophil count

**Timepoint**

The first day and the last day of the intervention

**Method of measurement**

blood analysis

### Secondary outcomes

empty

### Intervention groups

#### 1

**Description**

Intervention group: Includes 22 patients with COVID-19 who, in addition to their usual treatments, will take 3\*30 mg zinc capsules daily for 2 weeks (14 days) after meals.

**Category**

Treatment - Drugs

#### 2

**Description**

Control group: Includes 22 patients with COVID-19 who, in addition to their usual treatments, will take 3 placebo capsules (maltodextrin) daily for 2 weeks (14 days) after meals. Placebo capsules are exactly the same in appearance, color, smell and shape as zinc capsules.

**Category**

Placebo

### Recruitment centers

#### 1

**Recruitment center****Name of recruitment center**

Shohadaye Tajrish Educational Hospital

**Full name of responsible person**

Dr. Reza Jalili Khoshnood

**Street address**

Shohadaye Tajrish Educational Hospital Tajrish Sq.,  
Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

1989934148

**Phone**

+98 21 25719

**Email**

Pr\_shohada@sbm.ac.ir

**Web page address**

<http://shmc.sbm.ac.ir/index.jsp?fkeyid=&siteid=90&pageid=47435>

### Sponsors / Funding sources

#### 1

**Sponsor****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

آقای دکتر صحراييان

**Street address**

Vice Chancellor for Research and Technology, Central  
University Organization, sixth floor, corner of Quds  
Street, Keshavarz Boulevard

**City**

Tehran

**Province**

Tehran

**Postal code**

14155-6117

**Phone**

+98 21 8163 3685

**Fax****Email**

vcr@tums.ac.ir

**Web page address**

<http://en.tums.ac.ir/en>

**Grant name****Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

**Title of funding source**

Tehran University of Medical Sciences

**Proportion provided by this source**

100

**Public or private sector**

Public

**Domestic or foreign origin**

Domestic

**Category of foreign source of funding**

empty

**Country of origin****Type of organization providing the funding**

Academic

### Person responsible for general inquiries

**Contact****Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Seyed Morteza Seyed khamoushi

**Position**

Student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

School of Nutritional Sciences & Dietetics, Tehran  
University of Medical Sciences, No: 44 Hojjat-dost  
Alley, Naderi St., Keshavarz Blvd, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

3439123900

**Phone**

+98 21 8895 5975

**Fax**

+98 21 8898 4861

**Email**

mortezakhamoushi@gmail.com

**Person responsible for scientific inquiries**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Dr. Hossein Imani

**Position**

Associate professor

**Latest degree**

Ph.D.

**Other areas of specialty/work**

Nutrition

**Street address**

School of Nutritional Sciences & Dietetics, Tehran  
University of Medical Sciences, No: 44 Hojjat-dost  
Alley, Naderi St., Keshavarz Blvd, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

3439123900

**Phone**

+98 21 8895 5975

**Fax**

+98 21 8898 4861

**Email**

h-imani@sina.tums.ac.ir

**Person responsible for updating data**

**Contact**

**Name of organization / entity**

Tehran University of Medical Sciences

**Full name of responsible person**

Seyed Morteza Seyed khamoushi

**Position**

Student

**Latest degree**

Bachelor

**Other areas of specialty/work**

Nutrition

**Street address**

School of Nutritional Sciences & Dietetics, Tehran  
University of Medical Sciences, No: 44 Hojjat-dost  
Alley, Naderi St., Keshavarz Blvd, Tehran, Iran

**City**

Tehran

**Province**

Tehran

**Postal code**

3439123900

**Phone**

+98 21 8895 5975

**Fax**

+98 21 8898 4861

**Email**

mortezakhamoushi@gmail.com

**Sharing plan**

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

All information can be shared two months after the results are published.

**When the data will become available and for how long**

Two months after the results are published.

**To whom data/document is available**

Doctors, nurses, and infectious disease specialists

**Under which criteria data/document could be used**

To evaluate other complementary therapies and compare their effects with existing COVID-19 therapy

**From where data/document is obtainable**

Send email to mortezakhamoushi@gmail.com

**What processes are involved for a request to access data/document**

Two months publishing results, send a clear written request by sending an email to mortezakhamoushi@gmail.com. In this case, and finally within one month after receiving the email, the request will be answered.

**Comments**